Designed to move pharma further
BioNanoSim is backed by strong leadership, the collective know-how of a talented cross-functional team, and affiliation with the Hebrew University. These enable us to target multiple areas of unmet needs simultaneously. Our inhouse GMP facility is the perfect platform for the manufacturing of independent nanocarrier-based drugs for clinical testing.
HUJI affiliationExclusive license agreements covering multiple technologies
manufacturingInhouse 450 m2 GMP facility and API laboratory
PartnershipsMultiple partnerships in place, academic to commercial
Rich IPStrong patent portfolio made up of 5 patent families
Prof. Simon Benita
Ph.D., Founder, CEO
Mr. Alon Moran
Dr. Taher Nassar
Dr. Amit Badihi
Ph.D., VP R&D
Dr. Naama Adi-Hen
Ph.D., Director, QA/QC
Dr. Noam Freeman
PhD., Director, Chemistry R&D
Board of Directors
Prof. Simon Benita, Ph.D., Founder, CEO, and Chairman+-
Prof. Simon Benita, Ph.D., Founder, CEO, and Chairman
Prof. Benita has acquired decades of experience as well as proven commercial success in nanoparticle research. His most recent initiatives include the development of Ikervis<sup>TM</sup>, a revolutionary treatment for dry eye syndrome (DES) that was acquired and launched by Santen in 2015 and is now an established market leader in Europe.
Prof. Benita’s research focuses on new microparticulate and nanoparticulate targetable drug delivery systems (microspheres, microcapsules, nanoparticles, nanocapsules), and the design of antibody-emulsion or nanoparticle conjugates and modified nano-emulsions. He is the author of 159 original articles and review articles, 20 book chapters, and 35 patents and patent applications. Prof. Benita received full professorship at the School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem in 1994 and from 2010-2014 served as the Head of the School.Prof. Benita has accumulated decades of experience as well as proven commercial success in nanoparticle research. The most recent includes the development of Ikervis<sup>TM</sup>, a revolutionary treatment for dry eye syndrome (DES) that was acquired and launched by Santen in 2015 and is now an established market leader in Europe.
Prof. Benita’s research focuses on new microparticulate and nanoparticulate targetable drug delivery systems (microspheres, microcapsules, nanoparticles, nanocapsules), and the design of antibody-emulsion or nanoparticle conjugates and modified nano-emulsions. He is author of 159 original articles and review articles, 20 book chapters, and 35 patents and patent applications. Prof. Benita received full professorship at the School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem in 1994 and from 2010-2014 served as the Head of the School.
Mr. I. Steven Edelson, Director+-
Mr. I. Steven Edelson, Director
Mr. I. Steven Edelson, is the founder of The Mercantile Companies Inc. and IFG Development Group LLC and co-founder of IFG LLC. Mr. Edelson has overseen private equity funds as a principal of The Mercantile Capital Group. Mr. Edelson is an active investor in private placements, mezzanine investments, buyouts, and bridge and project financing. One of these investments was the private company Advanced Medicine, which later transformed into Theravance Biopharma, a public company currently trading on NASDAQ.
He has also been involved in public offerings and managing public companies. One of these companies, NASDAQ-listed Service Acquisition Corp, purchased Jamba Juice in 2006 when Mr. Edelson was Vice Chairman. Mr. Edelson is currently a Board Member of Lawson Products Inc., which is traded on NASDAQ. Mr. Edelson is a 2005 recipient of the Ellis Island Medal of Honor. He sits on the Board of Governors of the Hebrew University in Jerusalem and is a Trustee of the Harry S. Truman Institute for Peace. Mr. Edelson is a graduate of Roosevelt University.
Mrs. Joelle Aflalo, Director+-
Mrs. Joelle Aflalo, Director
Mrs. Joelle Aflalo is the Founding Member, CEO, and Managing Director of Gestman SA and Founding Member of Cofidom-Gestman Sàrl. These companies established in Luxembourg specialize in high-value and high-level corporate structuring and investment engineering. Mrs. Aflalo skills and her professionalism have facilitated the rapid growth of several high-profile companies. She holds a B.Sc. from the University Mohamed v in Rabat, Morocco, in Biology-Geology. Mrs. Aflalo is also the Founding Member and President of Matanel Foundation and Board Member of various charitable foundations and numerous large companies. She is considered a major influence in the financial industry in Luxembourg and other financial centers.
Dr. Keren-Or Amar, Ph.D.+-
Dr. Keren-Or Amar, Ph.D.
Dr. Amar earned her Ph.D. at the Faculty of Life Science, Bar-Ilan University, and completed post-doctoral studies at the Lautenberg Center for Immunology and Cancer Research at the Faculty of Medicine, Hebrew University, Jerusalem. She holds a BSc and MSc from the Faculty of Biology at the Technion Israel Institute of Technology, as well as an MA in Law from Bar-Ilan University. Since graduating, she has held a few management positions in the Biomed and Pharma Industries. Dr. Amar established and managed the research and development authority at Shaare Zedek Medical Center, served as the manager of ShizimXL medical devices accelerator and as global medical marketing manager for Panaxia pharmaceutical industries. Currently, Dr. Amar serves as the VP Business Development, Healthcare at Yissum- the Tech Transfer company of the Hebrew University of Jerusalem.
Prof. Yossi Tam, Scientific Advisory Board Member+-
Prof. Yossi Tam, Scientific Advisory Board Member
Prof. Yossi Tam received his B.Med.Sc., M.Sc., Ph.D., and D.M.D. from the Hebrew University of Jerusalem. Prof Tam completed his postdoctoral training at the National Institutes of Health (NIH). Since 2014 has headed the Obesity and Metabolism Laboratory at the Institute for Drug Research, where he is focused on targeting the endocannabinoid system for Obesity, Diabetes, and metabolic syndrome. Prof. Tam won major national and international grants and has authored over 45 peer-reviewed papers. He also serves as the Director of Hebrew University’s Multidisciplinary Center for Cannabinoid Research and a Scientific Advisory Board Member of several biotech companies, which develop a portfolio of non-psychoactive cannabinoid and cannabinoid-modulating medicines for unmet market needs. With his clinical background and science training, Prof. Tam has always been interested in how science can directly improve people’s everyday lives. Thus, he has strived unceasingly to integrate his clinical curiosity and experimental knowledge to deepen the understanding of clinically relevant research questions.
Dr. Ari Kellen , Strategic and Scientific Advisory Board Member+-
Dr. Ari Kellen , Strategic and Scientific Advisory Board Member
Dr. Ari Kellen is an experienced senior executive with over three decades of healthcare industry experience. After practicing medicine and running a large segment of the Johannesburg Hospital in South Africa, Dr. Kellen was recruited to McKinsey & Company where he spent 22 years as a strategic advisor to boards of directors and CEOs of major health care clients across the globe. In 2014 Dr. Kellen was recruited to Valeant Pharmaceuticals. Running US Bausch + Lomb, R&D, Latin America and Dermatology, he helped lead the company through a change in leadership and business strategy, and was subsequently promoted by the new CEO and Board to global segment lead of Bausch + Lomb. Since 2017 Dr. Kellen has been serving as a strategic advisor and investor to early-stage innovative healthcare companies in the US, Europe, and Israel. He is a graduate of Witwatersrand University in South Africa where he received his Medical and MBA degrees with distinction.
The most fruitful basis for the discovery of a new drug
is to start with an old drugSir James W. Black1988 Nobel Prize in Physiology / Medicine